News articles about MediciNova (NASDAQ:MNOV) have been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. MediciNova earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.5450247439127 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Separately, Credit Suisse Group initiated coverage on shares of MediciNova in a research report on Tuesday, April 18th. They set an “outperform” rating on the stock.

Shares of MediciNova (NASDAQ MNOV) traded up 3.84% on Monday, hitting $4.60. 72,282 shares of the stock traded hands. MediciNova has a 52-week low of $4.40 and a 52-week high of $7.78. The firm’s market cap is $161.31 million. The firm has a 50 day moving average price of $5.13 and a 200 day moving average price of $5.63.

TRADEMARK VIOLATION NOTICE: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at

MediciNova Company Profile

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Insider Buying and Selling by Quarter for MediciNova (NASDAQ:MNOV)

Receive News & Stock Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related stocks with our FREE daily email newsletter.